Biotherapy of Breast Cancer with EGF-Genistein
Final rept. 16 Sep 1996-15 Sep 2000
MINNESOTA UNIV MINNEAPOLIS
Pagination or Media Count:
The major goal of this research project was to optimize the conjugation procedures used in the preparation of the EGF-Gen conjugates in order to overcome the major limitations of this technology, including 1 instability of the conjugates 2 presence of Gen-free modified EGF in the conjugate preparations 3 slow kinetics of cell kill and 4 low yield of intact conjugate. The research did not lead to a solution for any of the above listed problemslimitations of the technology. It is therefore unlikely that the Genistein conjugates of EGF will be clinically useful. We have explored the potential of EGF conjugates containing other more active inhibitors of the EGF tyrosine kinase. While these conjugates have not been tested in animal models of breast cancer during the term of this grant, they are unlikely to offer significant advantages over the unconjugated small molecule tyrosine kinase inhibitors.
- Anatomy and Physiology
- Medicine and Medical Research